News Article
STUDIO CITY, CA, March 14, 2024 — The International Myeloma Foundation (IMF) is thrilled to welcome lifelong philanthropist and 17-year myeloma survivor John O’Dwyer to the IMF Board.
Prior to his recent election, John served on the IMF Board from 2010-2016 and made many…
Videos
Insights from the iStopMM Project: Preventing Myeloma Progression
Myeloma expert Dr. Brian G.M. Durie discusses how the iStopMM project in Iceland is studying myeloma at the earliest stage, specifically at the point of MGUS, to potentially prevent progression to active…
News Article
Myeloma Support Group Leader Voices at ASH
By Robin Tuohy, IMF Vice President, Support Groups
Every year in December, the Annual Meeting & Exposition of the American Society of Hematology (ASH) serves as a premier opportunity for researchers and clinicians to…
Page
What Is Mezigdomide?Mezigdomide is a CELMoD agent that is being studied in many clinical trials with different drug combinations and in different myeloma patient populations.What Are CELMoDs?Cereblon (CRBN) E3 ligase modulators (CELMoDs) are a new drug class in…
Page
What Is Iberdomide?Iberdomide is a CELMoD agent that is being studied in many clinical trials with different drug combinations and in different myeloma patient populations.As of August 13, 2026, the FDA granted accelerated approval to ZENBEXUS™ (iberdomide) in…
IMF Person
With 17 years of expertise in continuing medical education, Joi joined the IMF in December 2023. Her extensive background includes invaluable contributions to project management teams, delivering excellence in outcomes and insights. Joi is driven by a profound commitment to project success,…
IMF Person
Sandy is a seasoned grants manager with extensive experience in project management and leading effective and compliant solutions for sponsorship funding processes as well as experience in public opinion research. Prior to joining the IMF, Sandy worked at Karyopharm Therapeutics, a…
News Article
Positive Results from the DREAMM-8 Phase III Trial of Blenrep in Myeloma Treatment
In a March 7, 2024 press release from GSK, the following was reported: "Positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in…
Videos
Mass Spectrometry for the Measurement of Multiple Myeloma Protein Levels
Myeloma expert Dr. Brian G.M. Durie explores the significance of mass spectrometry, a sensitive monitoring technique, in measuring myeloma protein levels for diagnosis and monitoring.
Dr. Durie…
News Article
Uniting Voices, Connecting Lives: Empowering Myeloma Communities Together
90 leaders of 74 myeloma support groups gathered for the 24th annual IMF Support Group Leaders Summit
By Robin Tuohy, IMF Vice President, Support Groups
Over the span of 24 years…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the February 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
International Myeloma Foundation (IMF) Launches #MyelomaActionMonth for 2024 March Myeloma Action Month
Partnering with GMAN, Global Campaign Focuses on Raising Awareness and Taking Action for Myeloma to Bring Hope to Patients and Care Partners
STUDIO CITY,…
News Article
According to a press release from Legend Biotech, "the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expansion of the CARVYKTI® label to include adult patients with relapsed and refractory multiple myeloma, who have received at least…
Videos
Real World Outcomes with Ide-Cel CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Dr. Surbhi Sidana discusses the largest real-world study that looks at the Ide-Cel CAR T-cell therapy in the relapsed/refractory multiple myeloma population.
Abstract Title:…
News Article
According to a press release from Regeneron, the U.S. FDA "has accepted for Priority Review the Biologics License Application (BLA) for linvoseltamab to treat adult patients with relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies. The target…
News Article
According to a February 20, 2023 press release from Johnson & Johnson, the U.S. FDA has "approved the supplemental Biologics License Application (sBLA) for TECVAYLI® (teclistamab-cqyv) for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients with relapsed or refractory…
Videos
Early Screening for Myeloma: Impact on the Face of Myeloma
Myeloma expert Dr. Brian G.M. Durie explores how the face of myeloma is changing with the help of early screening and detection of monoclonal spikes in individuals at risk for myeloma.
Dr. Durie discusses the…
Videos
Promising Early Safety Profile of P-BCMA-ALLO1 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma Patients
Dr. Dholaria Bhagirathbhai presents the early safety results of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma patients with measurable disease who have received a…
Videos
Determination Phase 3 Trial: RVd Alone Versus Rvd Plus Autologous Stem Cell Transplantation in Newly Diagnosed African American Patients
Dr. Paul G. Richardson reports on the use of RvD alone versus RvD alongside an autologous stem cell transplantation (ASCT) in the treatment of newly diagnosed…
Videos
Mezigdomide (MEZI) Combination Therapy for Relapsed/Refractory Multiple Myeloma – Insights from CC-92480-MM-002 Trial
Dr. Paul G. Richardson reports on the use of various mezigdomide combinations in the treatment of relapsed/refractory multiple myeloma. …
News Article
According to a press release from Pfizer, Health Canada has granted a Notice of Compliance with conditions (NOC/c) to ELREXFIOTM (elranatamab solution for injection), marking its approval for use in the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM).…
News Article
STUDIO CITY, CA, February 13, 2024 — The International Myeloma Foundation (IMF) is excited to announce the launch of the Iceland Cycling Expedition (ICE)—a 3-day, 2-night fundraiser biking tour set to take place from August 29 - September 4, 2024, in Reykjavik and around Iceland to…
Page
Asian Myeloma Network Annual Summit 2025
This meeting announcement is for the IMF Asian Myeloma Network Health Care Practitioner Membership. Questions can be directed to IMF AMN Executive Staff, Dan Navid or Lisa Paik ([email protected], [email protected])
Videos
Ice-T Sets The Record Straight On Multiple Myeloma, "It's Not Melanoma."
Let's talk about the most common blood cancer in African Americans.
It hits hard, but together, we can educate, fight, and raise awareness. Know the signs, symptoms. Talk to your doctor.
News Article
February 9, 2024 — You may have seen this renowned actor on NBC's "Law & Order." Or perhaps you've listened to his music on your playlists. But did you know that songwriter, actor, producer, and well-known artist Ice-T is on a mission to help raise awareness of…
News Article
The International Myeloma Foundation has recently announced the appointment of Dr. Poornima Parameswaran, the Chief Executive Officer and Co-founder of Trace Genomics, to its board. Poornima is a three-year myeloma warrior. This appointment underscores IMF's ongoing commitment to bridge cutting-…
News Article
On February 5, 2024, GSK announced results from an interim analysis of the DREAMM-7 phase III head-to-head trial evaluating belantamab mafodotin combined with bortezomib plus dexamethasone (BorDex) versus daratumumab plus BorDex in second-line and later treatment of relapsed or refractory multiple…
News Article
STUDIO CITY, CA, February 2, 2024—The International Myeloma Foundation (IMF) formally welcomed world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD as the foundation’s new Chairperson of the Board on Friday, February 2. …
Videos
Actor and Artist Ice-T Raises Awareness of Myeloma in the Black Community During Black History Month
Renowned actor and artist Ice-T joins hands with the International Myeloma Foundation to raise awareness of myeloma in the black community this Black History Month. The IMF's M-Power project is a…
News Article
On February 2, 2024, world-renowned myeloma clinician and researcher Dr. S. Vincent Rajkumar took on the full role as Chairperson of the International Myeloma Foundation (IMF) Board of Directors.
In a Q&A interview, Dr. Rajkumar shared some of his experiences, thoughts, and vision for the…
News Article
STUDIO CITY, Calif., Feb. 01, 2024 -- Working alongside the International Myeloma Foundation (IMF), American songwriter, actor, producer, and well-known artist Ice-T is on a mission to help raise awareness of multiple myeloma in the African American community.
Multiple…
Videos
Updates in Multiple Myeloma Care: Isatuximab Combo Outshines Standard Therapy in Iskia Trial for Pre- and Post-Transplant Treatment
Dr. Francesca Gay discusses the phase III IsKia trial, which studies the efficacy and safety of isatuximab-carfilzomib-lenalidomide-dexamethasone (IsaKRd) as…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the January 2024 edition.
The IMF team of medical editors has provided overviews of key studies. Yet, we…
Videos
Elranatamab, a BCMAxCD3 Bispecific Antibody, Demonstrates Effectiveness in Relapsed Myeloma Post-BCMA CAR-T Therapy
Dan Sherbenou, MD, PhD, discusses an elranatamab trial that aims to contribute vital insights into optimizing the sequencing of BCMA therapies and maximizing benefits for…
Videos
IMF Chief Medical Officer Dr. Joseph Mikhael Highlights Key Research from the ASH 2023 Meeting and Expo
Important Myeloma Research Presented at ASH 2023
Presented by Dr. Joseph Mikhael, IMF's Chief Medical Officer
In this insightful video, Dr. Joseph Mikhael, Chief Medical Officer of the…
News Article
STUDIO CITY, CA, January 22, 2024 — Today, the International Myeloma Foundation (IMF) announced with great sadness, the passing of one of the IMF’s Board Members, Clinical Professor of Medicine and Medical Oncology, Director of the Center to Eliminate Cancer Disparities at Sidney…
Videos
Extended Analysis Reveals Promising Patterns of Response to 200 Mg Linvoseltamab in Relapsed/Refractory Multiple Myeloma Patients – Linker-MM1 Study Follow-Up
Dr. Hans Lee discusses follow-up to the Linker-MM1 trial, which studied the safety and efficacy of…
Videos
Ide-Cel Versus Standard Regimens: Updated Insights for Triple-Class-Exposed RRMM Patients – Findings from KarMMa-3 Study
Dr. Rodríguez discusses the KarMMa-3 study, and how ide-cel compares to other regimens in the treatment of heavily pre-treated relapsed…
News Article
International Myeloma Foundation and the Black Swan Research Initiative Showcase Six Oral & Poster Abstracts by the iStopMM Project at the 2023 ASH Annual Meeting
iStopMM team members Thorir Einarsson Long, Jon Thorir Oskarsson, and Sæmundur Rognvaldsson are 2023 ASH Abstract…
Videos
Interim Safety Analysis of Selinexor and Lenalidomide Combo in Phase III Trial for Newly Diagnosed Multiple Myeloma (SeaLAND Study)
Dr. Quach discusses a phase III study that compares a combination of selinexor and lenalidomide to lenalidomide alone for transplant-eligible,…
Videos
Exploring the Safety and Efficacy of Sonrotoclax (BGB-11417) in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma with t(11;14) — Insights into Recommended Phase II Dose
Dr. Quach reports on the preliminary data from the sonrotoclax plus dexamethasone dose-escalation…
Videos
Enhancing Survival in Multiple Myeloma: A Breakdown of Frontline Treatments DRd vs. VRd for Transplant-Ineligible Patients
Dr. Doris K. Hansen discusses a study that compares real-world time-to-next-treatment (TTNT) or death between newly diagnosed multiple myeloma (NDMM), transplant-…
Videos
Myeloma Treatment: Abbv-383 BCMA x CD3 Bispecific Antibody Shows Promising Safety and Efficacy in Phase I Study for Relapsed/Refractory Patients
Dr. Ravi Vij reports on the safety and efficacy of Abbv-383 dosed intravenously, once every three weeks, in patients with relapsed/refractory…
Videos
Relapsed Multiple Myeloma Treatment: Long-Term Insights from GMMG Phase III Trial Comparing Salvage Autologous Transplant and Lenalidomide Maintenance to Continuous Lenalidomide/Dexamethasone
Dr. Marc-Andrea Baertsch reports on long-term, follow-up results from the GMMG ReLApsE trial.…
Videos
Each year, the IMF brings support group leaders from across the U.S. to the annual American Society of Hematology Meeting and Expo. Listen to a discussion hosted by IMF Chief Medical Officer, Dr. Joseph Mikhael.
Videos
Primary Results of Phase 3 Perseus Trial: Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) vs. Vrd Alone in Myeloma Patients Eligible for ASCT
Pieter Sonneveld, MD, PhD, discusses the results of the phase 3 Perseus Trial for myeloma patients eligible for autologous…
Videos
Myeloma Study with Promising First Results of Iberdomide Maintenance in Phase 2 EMN26 Study Post Stem-Cell Transplantation
Dr. Niels W.C.J. van de Donk discusses the safety and clinical activity of 3 different doses of iberdomide as a novel maintenance treatment post-…